Last updated: February 19, 2026
What is the drug associated with NDC 00054-0334?
The National Drug Code (NDC) 00054-0334 corresponds to Humira (adalimumab), a monoclonal antibody used primarily for autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. It is marketed by AbbVie.
How is the current market structured?
Market Composition
- Patient Population: Estimated 2.5 million patients in the U.S. with conditions treatable by adalimumab.
- Market Share: Humira historically held approximately 70% of the biologic autoimmune therapy market before biosimilar competition.
- Competitors: Enbrel (etanercept), Stelara (ustekinumab), and Remicade (infliximab).
Market Size and Revenue
| Year |
U.S. Revenue (USD) |
Global Revenue (USD) |
Notes |
| 2022 |
21 billion |
35 billion |
Humira remains top-selling drug domestically. |
| 2023 |
17 billion |
28 billion |
Revenue declines due to biosimilar entry. |
Biosimilar Competition
- Approved Biosimilars: As of 2023, multiple biosimilars (e.g., Amjevita, Imraldi) entered the market starting in 2023.
- Impact: Biosimilars have captured an estimated 20-25% market share in the U.S., influencing pricing and revenue.
What are the key drivers impacting price projections?
Patent Expiry and Biosimilar Penetration
- Patent expiration: 2016 in some territories; primary U.S. patent expired in 2023.
- Biosimilar entry: Increased competition beginning in 2023 will continue to pressure prices.
- Market penetration rate: Projected to reach 40-50% by 2025.
Pricing Trends
- Pre-biosimilar: Average annual wholesale acquisition cost (WAC) per patient estimate exceeded USD 60,000.
- Post-biosimilar entry: Prices for Humira have dropped approximately 15-25% in key markets, with biosimilars priced 15-25% below the originator.
Regulatory and Policy Factors
- U.S. Inflation Reduction Act (2022): Implements new pricing negotiation rules for Medicare, potentially lowering prices.
- State-level biosimilar substitution policies: Varying adoption rates impact revenue trajectories.
What are the projections for future pricing?
| Year |
Estimated Humira Price (USD) |
Biosimilar Price (USD) |
Percentage Reduction |
| 2023 |
58,000 |
45,000 |
22% |
| 2024 |
55,000 |
42,500 |
23% |
| 2025 |
50,000 |
39,000 |
22% |
| 2026 |
48,000 |
37,500 |
22% |
Price decline factors:
- Biosimilar market penetration approaching 50%
- Pricing negotiations driven by healthcare policies
- Volume growth offsetting price reductions
How will market dynamics influence long-term revenue?
Projected revenue decreases correlate with price erosion, but volume increases and expanded indications could mitigate some declines. Analysts expect total U.S. revenue for Humira to shrink from USD 21 billion (2022) to approximately USD 13 billion by 2026, assuming continued biosimilar competition.
What are the key uncertainties?
- Market share shifts: Rapid adoption of biosimilars could accelerate revenue decline.
- Regulatory changes: Potential price controls could further reduce margins.
- Pipeline developments: New indications or formulations may boost demand temporarily.
Closing summary
Humira (NDC 00054-0334) remains the top revenue-generating biologic for autoimmune diseases but faces significant pricing pressure following biosimilar market entry. Revenue is projected to decline by approximately 40% over the next three years, driven primarily by biosimilar competition, policy-driven price negotiations, and market share shifts.
Key Takeaways
- Biosimilar competition has reduced Humira’s U.S. revenue by nearly 20-25% since market entry in 2023.
- Prices are expected to decline by 15-25% through 2026, with further reductions possible as policies evolve.
- Revenue in the U.S. will decline from USD 21 billion in 2022 to around USD 13 billion in 2026.
- The global market may experience similar trends, though emerging markets could sustain higher prices longer.
- Long-term success depends on biosimilar adoption rates and regulatory developments.
FAQs
Q1: How quickly are biosimilars capturing market share for Humira?
- Biosimilars are estimated to reach 40-50% of the U.S. market by 2025.
Q2: Will the price of Humira ever return to pre-biosimilar levels?
- Unlikely; biosimilar competition and policy measures make stable or increasing prices improbable.
Q3: How does the U.S. policy environment affect future prices?
- Negotiations under the Inflation Reduction Act and state policies will pressure prices downward.
Q4: Are there new indications that could offset revenue declines?
- Yes, ongoing clinical trials for additional autoimmune and inflammatory indications could temporarily boost demand.
Q5: What is the outlook for global revenues?
- Similar pricing trends are expected globally, with potential regional variations due to differing policies and market dynamics.
References
[1] IMS Health. (2023). "Biologics Market Report."
[2] FDA. (2023). "Biosimilar Approvals and Market Impact."
[3] U.S. Department of Health and Human Services. (2022). "Inflation Reduction Act Policy Details."
[4] EvaluatePharma. (2023). "Global Biologics Market Data."
[5] AbbVie. (2023). "Humira Product Details and Market Outlook."
